Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMPH Amphastar Pharmaceuticals	$23.08 -0.4%	$24.79	$22.64 ▼ $53.96	$1.09B	0.77	497,082 shs	1.27 million shs
ARDX Ardelyx	$3.69 +0.3%	$4.00	$3.21 ▼ $8.06	$882.85M	0.59	4.49 million shs	3.11 million shs
PVLA Palvella Therapeutics	$22.08 +7.1%	$23.54	$6.20 ▼ $29.27	$244.12M	-0.1	83,806 shs	1.14 million shs
SNDX Syndax Pharmaceuticals	$9.04 -2.8%	$10.88	$8.58 ▼ $25.07	$777.86M	0.74	1.83 million shs	3.24 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMPH Amphastar Pharmaceuticals	-0.43%	-6.03%	-8.63%	-18.82%	-42.34%
ARDX Ardelyx	+0.27%	+3.65%	-5.63%	-25.15%	-39.61%
PVLA Palvella Therapeutics	+7.08%	+0.14%	-7.34%	-21.42%	+2,207,999,900.00%
SNDX Syndax Pharmaceuticals	-2.80%	-4.64%	-10.67%	-31.41%	-54.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMPH Amphastar Pharmaceuticals	4.2581 of 5 stars	3.1	2.0	3.7	1.5	4.2	1.3
ARDX Ardelyx	4.433 of 5 stars	3.5	3.0	4.4	2.7	2.5	0.6
PVLA Palvella Therapeutics	3.2346 of 5 stars	3.6	0.0	0.0	2.5	4.2	0.6
SNDX Syndax Pharmaceuticals	3.2017 of 5 stars	3.5	1.0	4.4	1.8	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMPH Amphastar Pharmaceuticals	2.25	Hold	$32.33	40.09% Upside
ARDX Ardelyx	3.00	Buy	$10.89	195.09% Upside
PVLA Palvella Therapeutics	3.13	Buy	$46.29	109.63% Upside
SNDX Syndax Pharmaceuticals	2.90	Moderate Buy	$35.80	296.02% Upside

Current Analyst Ratings Breakdown

Latest PVLA, ARDX, SNDX, and AMPH Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
5/16/2025	PVLA Palvella Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$53.00 ➝ $52.00
5/12/2025	AMPH Amphastar Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral	$45.00 ➝ $30.00
5/8/2025	AMPH Amphastar Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$40.00 ➝ $35.00
5/6/2025	SNDX Syndax Pharmaceuticals	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$16.00 ➝ $17.00
5/6/2025	SNDX Syndax Pharmaceuticals	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00 ➝ $32.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
4/30/2025	PVLA Palvella Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/10/2025	AMPH Amphastar Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
4/9/2025	PVLA Palvella Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00

(Data available from 6/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMPH Amphastar Pharmaceuticals	$731.97M	1.49	$5.01 per share	4.61	$15.23 per share	1.52
ARDX Ardelyx	$333.61M	2.65	N/A	N/A	$0.73 per share	5.05
PVLA Palvella Therapeutics	$42.81M	5.70	N/A	N/A	$5.58 per share	3.96
SNDX Syndax Pharmaceuticals	$23.68M	32.85	N/A	N/A	$3.38 per share	2.67

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMPH Amphastar Pharmaceuticals	$159.52M	$2.76	8.36	7.02	6.01	19.38%	22.20%	10.40%	8/6/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.22	N/A	11.90	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
PVLA Palvella Therapeutics	-$17.43M	-$12.10	N/A	N/A	N/A	N/A	-60.29%	-43.30%	8/13/2025 (Estimated)
SNDX Syndax Pharmaceuticals	-$318.76M	-$3.86	N/A	N/A	N/A	-757.53%	-101.60%	-58.41%	8/7/2025 (Estimated)

Latest PVLA, ARDX, SNDX, and AMPH Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	PVLA Palvella Therapeutics	-$3.40	-$0.74	+$2.66	-$0.74	N/A	N/A
5/5/2025	Q1 2025	SNDX Syndax Pharmaceuticals	-$1.04	-$0.98	+$0.06	-$0.98	$15.88 million	$20.04 million
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMPH Amphastar Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
PVLA Palvella Therapeutics	N/A	N/A	N/A	N/A	N/A
SNDX Syndax Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMPH Amphastar Pharmaceuticals	0.80	2.95	2.02
ARDX Ardelyx	1.04	4.12	3.81
PVLA Palvella Therapeutics	N/A	8.84	8.84
SNDX Syndax Pharmaceuticals	1.53	5.80	5.75

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMPH Amphastar Pharmaceuticals	65.09%
ARDX Ardelyx	58.92%
PVLA Palvella Therapeutics	40.11%
SNDX Syndax Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AMPH Amphastar Pharmaceuticals	27.50%
ARDX Ardelyx	4.80%
PVLA Palvella Therapeutics	20.50%
SNDX Syndax Pharmaceuticals	4.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMPH Amphastar Pharmaceuticals	2,028	47.14 million	34.18 million	Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
PVLA Palvella Therapeutics	N/A	11.06 million	8.79 million	N/A
SNDX Syndax Pharmaceuticals	110	86.05 million	82.52 million	Optionable

PVLA, ARDX, SNDX, and AMPH Headlines

Recent News About These Companies

Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance

June 27 at 7:18 PM | finance.yahoo.com

SNDX Syndax Pharmaceuticals, Inc. - Seeking Alpha

June 26 at 1:22 PM | seekingalpha.com

Syndax Pharmaceuticals Inc News (SNDX) - Investing.com

June 26 at 8:21 AM | investing.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia - Morningstar

June 25 at 8:50 PM | morningstar.comM

Syndax Gets Priority Review for Leukemia Drug Application

June 24, 2025 | marketwatch.com

Syndax stock rises after FDA grants Priority Review for cancer drug expansion

June 24, 2025 | investing.com

Syndax Pharmaceuticals Publishes Positive Revumenib Data from BEAT AML Trial

June 24, 2025 | msn.com

Syndax Announces FDA Priority Review of sNDA for Revuforj® (revumenib) in Relapsed or Refractory mNPM1 Acute Myeloid Leukemia

June 24, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/24/3104643/0/en/syndax-announces-fda-priority-review-of-snda-for-revuforj-revumenib-in-relapsed-or-refractory-mnpm1-acute-myeloid-leukemia.html$

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives $35.91 Average PT from Brokerages

June 24, 2025 | americanbankingnews.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Given Consensus Rating of "Moderate Buy" by Brokerages

June 21, 2025 | marketbeat.com

Syndax reports publication of revumenib data from BEAT AML trial

June 13, 2025 | msn.com

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Sold by Assenagon Asset Management S.A.

June 13, 2025 | marketbeat.com

Syndax Pharmaceuticals (NASDAQ:SNDX) Shares Down 3.7% - Time to Sell?

June 12, 2025 | marketbeat.com

Syndax Pharma releases new data from its AUGMENT-101 trial of Revuforj

June 12, 2025 | thepharmaletter.comT

Syndax Announces Publication of Revumenib Data from the BEAT AML Trial in the Journal of Clinical Oncology and Simultaneous Presentation at EHA 2025

June 12, 2025 | globenewswire.com

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

June 12, 2025 | globenewswire.com $https://www.globenewswire.com/news-release/2025/06/12/3098182/0/en/syndax-presents-new-revuforj-revumenib-data-in-relapsed-refractory-mnpm1-and-nup98r-acute-leukemia-from-augment-101-trial-at-eha-2025.html$

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

June 7, 2025 | marketbeat.com

Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

June 5, 2025 | globenewswire.com

Ameriprise Financial Inc. Has $423,000 Position in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 5, 2025 | marketbeat.com

Kura Posts New Data, Secures NDA Acceptance in Acute Myeloid Leukemia Race With Syndax

June 3, 2025 | biospace.comB

Nuveen Asset Management LLC Trims Stock Holdings in Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

June 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVLA, ARDX, SNDX, and AMPH Company Descriptions

Amphastar Pharmaceuticals NASDAQ:AMPH

$23.08 -0.10 (-0.43%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$23.49 +0.41 (+1.78%)

As of 06/27/2025 06:05 PM Eastern

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company provides Amphadase, an injection to absorb and disperse other injected drugs; Epinephrine injection for allergic reactions; Lidocaine jelly, an anesthetic product for urological procedures; Lidocaine topical solution for various procedures; Phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products; morphine injection for use with patient-controlled analgesia pumps; and Lorazepam injection for surgery and medical procedures. In addition, it offers Neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; Isoproterenol hydrochloride injection for mild or transient episodes of heart block; Ganirelix Acetate injection for the inhibition of premature luteinizing hormone surges; Vasopressin to increase blood pressure; and Regadenoson, a stress agent for radionuclide myocardial perfusion imaging. Further, the company distributes recombinant human insulin APIs and porcine insulin API. Additionally, it develops generic product candidates, such as injectable, inhalation, and analytical technologies; biosimial product candidates; and intranasal epinephrine for the treatment of allergic reactions. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Ardelyx NASDAQ:ARDX

$3.69 +0.01 (+0.27%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$3.70 +0.02 (+0.41%)

As of 06/27/2025 07:23 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Palvella Therapeutics NASDAQ:PVLA

$22.08 +1.46 (+7.08%)

As of 06/27/2025 04:00 PM Eastern

Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.

Syndax Pharmaceuticals NASDAQ:SNDX

$9.04 -0.26 (-2.80%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$9.18 +0.15 (+1.60%)

As of 06/27/2025 07:12 PM Eastern

Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF). The company is also developing Entinostat. It has an agreement with Eddingpharm International Company Limited for licensing, development, and commercialization of Entinostat. Syndax Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Waltham, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time